Drugs / CD38 CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05239689 | Feb 2022 → Dec 2024 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD38 CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05239689 ↗ |
| Known as | CD38 CAR T-cells injection | “Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection” NCT05239689 ↗ |
| Modality | Cell therapy | “The CAR-T cell injection uses immune cells from healthy donors” NCT05239689 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT05239689 ↗ |
| Target | CD38 | “treatment of targeting CD38” NCT05239689 ↗ |